OBI-833/OBI-821 Maintenance for Bile Duct or Gallbladder Cancer
Part of Cancer clinical trials.
This study tests a maintenance treatment called OBI-833/OBI-821 for people with bile duct or gallbladder cancer that has a specific marker (Globo H). After about 3 months of standard chemo (gemcitabine/cisplatin), you continue that chemo and add this investigational vaccine-like drug to see if it keeps the cancer stable longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have advanced or metastatic cancer of the bile ducts or gallbladder that cannot be removed by surgery.
- You have been receiving your first treatment with gemcitabine and cisplatin (GemCis) for about 3 months and your cancer has not grown (it's stable or smaller).
- You had a biopsy that shows your cancer has a marker called 'Globo H' in high amounts.
- You are in good physical shape (able to do normal activities) and your liver, kidney, and blood counts are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial is for people with advanced biliary tract cancer who have already completed at least 8 cycles of a specific immunotherapy-chemo combination and are now moving to a maintenance phase with just the immunotherapy. It tests whether continuing a different immunotherapy alone can help keep the cancer from coming back longer.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.